Fig. 4: mRNA sequencing reveals miR-99a-5p inhibition alters key type-2 immune pathways in the lung during AAI. | Mucosal Immunology

Fig. 4: mRNA sequencing reveals miR-99a-5p inhibition alters key type-2 immune pathways in the lung during AAI.

From: Inhibition of miR-99a-5p prevents allergen-driven airway exacerbations without compromising type-2 memory responses in the intestine following helminth infection

Fig. 4

a The number of common and distinct differentially expressed genes in the lungs of HDM-treated mice that received individual miRNA-inhibitor treatment (relative to PBS control, RPKM > 1, FDR > 0.05). b The top 24 most up-regulated differentially expressed genes in the lungs of control inhibitor-treated HDM mice and their expression in miRNA-inhibitor-treated HDM mice (Fold change relative to PBS, RPKM > 1, FDR > 0.05), N.D. no difference. c Selected expression profiles of key genes in allergic airway inflammation following HDM challenge and miRNA-inhibitor treatment. n = 5 mice per group from one experiment. *p < 0.05; **p < 0.01, determined using a Mann–Whitney test. N.D. denotes not differentially expressed.

Back to article page